Back

Echocardiographic changes with mavacamten in patients with obstructive hypertrophic cardiomyopathy: early experience from a referral center

12 December 2025 (08:30 - 09:15)
Organised by: Logo
Congress Presentation Part of: What is new in hypertrophic cardiomyopathy Myocardial Disease EACVI Premium Access EACVI 2025 European Association of Cardiovascular Imaging (EACVI)

About the speaker

Photo
Doctor Leandro Santiago Videla

University Hospital Vall d'Hebron, Barcelona (Spain)

6 More presentations in this session

Presentation thumbnail
Innovative markers of left atrial remodeling in the prediction of exercise capacity in sarcomeric hypertrophic cardiomyopathy
Mr A. Melot (Rennes, FR)
Abstract Slides
Presentation thumbnail
Echocardiographic parameters of left ventricular diastolic dysfunction, left atrial volumes and left atrial function improves in obstructive hypertrophic cardiomyopathy during mavacamten treatment
Doctor A. Kormanyos (Szeged, HU)
Abstract Slides
Presentation thumbnail
Echocardiographic drag effect index predicts response to mavacamten in obstructive hypertrophic cardiomyopathy
Doctor J. Ha (Seoul, KR) Associate Professor I. Cho (Seoul, KR)
Abstract Slides
Presentation thumbnail
Right-sided cardiac echocardiographic parameters show no major change during 3-months mavacamten treatment in obstructive hypertrophic cardiomyopathy
Doctor N. Schvartz (Szeged, HU)
Abstract Slides
Presentation thumbnail
Left atrial total emptying fraction is the main predictor of atrial fibrillation in patients with hypertrophic cardiomyopathy
Doctor I. Cergan (Bucharest, RO)
Abstract Slides

Access the full session

Session thumbnail
What is new in hypertrophic cardiomyopathy

The Event

Event poster

EACVI 2025

12 December 2025 08:30 CET
You may be interested in
thumbnail
Congress Session
Recent advances in clinical practice guidelines: what the imager needs to know and apply - Part 2
thumbnail
Congress Session
Advanced imaging in heart failure
thumbnail
Congress Session
When external causes are the villain?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources